← Back to headlines
Biogen Acquires Apellis for $5.6 Billion in Rare Disease Expansion
Biogen is making a strategic move into the rare disease market with a $5.6 billion acquisition of Apellis Pharmaceuticals, aiming to expand its portfolio in this specialized area.
31 Mar, 15:15 — 31 Mar, 15:15
Sources
Showing 1 of 1 sources
